<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23339605</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2013</Year><Month>Jan</Month><Day>22</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Strategies to develop antivirals against enterovirus 71.</ArticleTitle><Pagination><StartPage>28</StartPage><MedlinePgn>28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-422X-10-28</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is an important human pathogen which may cause severe neurological complications and death in children. The virus caused several outbreaks in the Asia-Pacific region during the past two decades and has been considered a significant public health problem in the post-poliovirus eradication era. Unlike poliovirus, there is no effective vaccine or approved antivirals against EV71. To explore anti-EV71 agents therefore is of vital importance. Several strategies have been employed to develop antivirals based on the molecular characteristics of the virus. Among these, some small molecules that were developed against human rhinoviruses and poliovirus are under evaluation. In this review, we discuss the recent development of such small molecules against EV71, known drug resistance and possible solutions to it, and animal models for evaluating the efficacy of these antivirals. Although further investigation is required for clinical applications of the existing candidates, the molecular mechanisms revealed for the inhibition of EV71 replication can be used for designing new molecules against this virus in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Rei-Lin</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Research Center for Emerging Viral Infections, Chang Gung University, 259 Wen-Hua 1st Road, Kwei-Shan, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Shin-Ru</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23339605</ArticleId><ArticleId IdType="pmc">PMC3614426</ArticleId><ArticleId IdType="doi">10.1186/1743-422X-10-28</ArticleId><ArticleId IdType="pii">1743-422X-10-28</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;10(3):304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuBakar S, Sam IC, Yusof J, Lim MK, Misbah S, MatRahim N, Hooi PS. Enterovirus 71 outbreak, Brunei. Emerg Infect Dis. 2009;10(1):79&#x2013;82. doi: 10.3201/eid1501.080264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1501.080264</ArticleId><ArticleId IdType="pmc">PMC2660687</ArticleId><ArticleId IdType="pubmed">19116058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;10(13):929&#x2013;935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Utama A, Yoshii K, Yoshida H, Yoneyama T, Sinniah M, Yusof MA, Okuno Y, Okabe N, Shih SR. et al.Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis. 1999;10(1):12&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10808253</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J. et al.Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol. 2009;10(7):2351&#x2013;2352. doi: 10.1128/JCM.00563-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00563-09</ArticleId><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS. et al.Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999;10(9191):1682&#x2013;1686. doi: 10.1016/S0140-6736(99)04434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A. et al.An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;10:94. doi: 10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiff A. Cambodia unravels cause of mystery illness. Lancet. 2012;10(9838):206. doi: 10.1016/S0140-6736(12)61201-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61201-X</ArticleId><ArticleId IdType="pubmed">22826834</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;10(11):1097&#x2013;1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, Wang JR, Liu CC, Lei HY, Yu CK. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol. 2007;10(17):8996&#x2013;9003. doi: 10.1128/JVI.00236-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00236-07</ArticleId><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;10(2&#x2013;3):195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;10(7):794&#x2013;797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;10(7):798&#x2013;801. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson SR, Sarnow P. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Virology. 2003;10(1):259&#x2013;266. doi: 10.1016/S0042-6822(03)00544-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0042-6822(03)00544-0</ArticleId><ArticleId IdType="pubmed">14592777</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello VR. In: Fields Virology. 5th. Knipe DM, Howley PM, editor. Philadelphia, PA, USA: Lippincott Williams &amp; Wilkins; 2007. Picornaviridae: The Virus ans Their Repliation; pp. 796&#x2013;839.</Citation></Reference><Reference><Citation>Rust RC, Landmann L, Gosert R, Tang BL, Hong W, Hauri HP, Egger D, Bienz K. Cellular COPII proteins are involved in production of the vesicles that form the poliovirus replication complex. J Virol. 2001;10(20):9808&#x2013;9818. doi: 10.1128/JVI.75.20.9808-9818.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.20.9808-9818.2001</ArticleId><ArticleId IdType="pmc">PMC114553</ArticleId><ArticleId IdType="pubmed">11559814</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WF, Yang SY, Wu BW, Jheng JR, Chen YL, Shih CH, Lin KH, Lai HC, Tang P, Horng JT. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. J Biol Chem. 2007;10(8):5888&#x2013;5898.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CY, Lee CY, Kao CL, Shao WY, Lee PI, Twu SJ, Yeh CC, Lin SC, Shih WY, Wu SI. et al.Incidence and case-fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. J Med Virol. 2002;10(2):217&#x2013;223. doi: 10.1002/jmv.2210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.2210</ArticleId><ArticleId IdType="pubmed">11992582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo RL, Kung SH, Hsu YY, Liu WT. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J Gen Virol. 2002;10(Pt 6):1367&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12029152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999;10(12):1092&#x2013;1096. doi: 10.1097/00006454-199912000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199912000-00013</ArticleId><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microb Infec. 2007;10(11):1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci. 2000;10(6):523&#x2013;528. doi: 10.1007/BF02253368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02253368</ArticleId><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;10(1):61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004;10(5):1766&#x2013;1772. doi: 10.1128/AAC.48.5.1766-1772.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.5.1766-1772.2004</ArticleId><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="pubmed">15105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Florea NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy. 2003;10(3):339&#x2013;348. doi: 10.1592/phco.23.3.339.32099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.23.3.339.32099</ArticleId><ArticleId IdType="pmc">PMC7168037</ArticleId><ArticleId IdType="pubmed">12627933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother. 1992;10(4):727&#x2013;732. doi: 10.1128/AAC.36.4.727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.4.727</ArticleId><ArticleId IdType="pmc">PMC189373</ArticleId><ArticleId IdType="pubmed">1503435</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001;10(2):228&#x2013;235. doi: 10.1086/318452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318452</ArticleId><ArticleId IdType="pubmed">11170912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y. et al.In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;10(4):669&#x2013;679. doi: 10.1007/s00705-011-1222-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia KS, Li WT, Chang CM, Hsu MC, Chern JH, Leong MK, Tseng SN, Lee CC, Lee YC, Chen SJ. et al.Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem. 2002;10(8):1644&#x2013;1655. doi: 10.1021/jm010536a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm010536a</ArticleId><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC. et al.Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother. 2004;10(9):3523&#x2013;3529. doi: 10.1128/AAC.48.9.3523-3529.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh TM. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 2005;10(1):31&#x2013;37. doi: 10.1016/j.antiviral.2005.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2005.03.005</ArticleId><ArticleId IdType="pubmed">15916817</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT. et al.Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A. 1999;10(20):11000&#x2013;11007. doi: 10.1073/pnas.96.20.11000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Shih SR, Chang TY, Tseng HY, Shih YF, Yen KJ, Chen WC, Shie JJ, Fang JM, Liang PH. et al.A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal Biochem. 2008;10(1):115&#x2013;123. doi: 10.1016/j.ab.2007.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2007.12.019</ArticleId><ArticleId IdType="pubmed">18190777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Qi J, Chen Z, Xu X, Gao F, Lin D, Qian W, Liu H, Jiang H, Yan J. et al.Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011;10(19):10319&#x2013;10331. doi: 10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MT, Cheng YH, Liu YN, Liao NC, Lu WW, Kung SH. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob Agents Chemother. 2009;10(2):748&#x2013;755. doi: 10.1128/AAC.00841-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00841-08</ArticleId><ArticleId IdType="pmc">PMC2630644</ArticleId><ArticleId IdType="pubmed">19015331</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA. et al.In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;10(6):2267&#x2013;2275. doi: 10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, Wang J, Fan T, Qin B, Guo L, Lei X, Wang M, Jin Q. Crystal structure of human enterovirus 71 3C protease. J Mol Biol. 2011;10(3):449&#x2013;461. doi: 10.1016/j.jmb.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.03.007</ArticleId><ArticleId IdType="pmc">PMC7094522</ArticleId><ArticleId IdType="pubmed">21396941</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen JF, Cherney MM, Liebig HD, Skern T, Kuechler E, James MN. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. EMBO J. 1999;10(20):5463&#x2013;5475. doi: 10.1093/emboj/18.20.5463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/18.20.5463</ArticleId><ArticleId IdType="pmc">PMC1171615</ArticleId><ArticleId IdType="pubmed">10523291</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter NJ, Roetzer A, Liebig HD, Sedelnikova SE, Hounslow AM, Skern T, Waltho JP. Structure and dynamics of coxsackievirus B4 2A proteinase, an enyzme involved in the etiology of heart disease. J Virol. 2006;10(3):1451&#x2013;1462. doi: 10.1128/JVI.80.3.1451-1462.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.3.1451-1462.2006</ArticleId><ArticleId IdType="pmc">PMC1346940</ArticleId><ArticleId IdType="pubmed">16415022</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris N, De Palma A, Toussaint JF, Musch I, Neyts J, De Clercq K. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 2007;10(3):161&#x2013;168. doi: 10.1016/j.antiviral.2006.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2006.09.007</ArticleId><ArticleId IdType="pubmed">17055073</ArticleId></ArticleIdList></Reference><Reference><Citation>Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, Peterson BR. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J Med Chem. 2006;10(21):6166&#x2013;6169. doi: 10.1021/jm060872x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm060872x</ArticleId><ArticleId IdType="pmc">PMC2094219</ArticleId><ArticleId IdType="pubmed">17034123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol. 1988;10(5):1334&#x2013;1341. doi: 10.1016/0735-1097(88)92618-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(88)92618-6</ArticleId><ArticleId IdType="pubmed">2844874</ArticleId></ArticleIdList></Reference><Reference><Citation>Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger JM Jr, Peterson BR, Loakes D. et al.Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob Agents Chemother. 2008;10(3):971&#x2013;979. doi: 10.1128/AAC.01056-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01056-07</ArticleId><ArticleId IdType="pmc">PMC2258490</ArticleId><ArticleId IdType="pubmed">18180344</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Chang HY, Lin PF, Chern JH, Hsu JT, Chang CY, Shih SR. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009;10(7):2740&#x2013;2747. doi: 10.1128/AAC.00101-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00101-09</ArticleId><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>He R, Adonov A, Traykova-Adonova M, Cao J, Cutts T, Grudesky E, Deschambaul Y, Berry J, Drebot M, Li X. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem Biophys Res Commun. 2004;10(4):1199&#x2013;1203. doi: 10.1016/j.bbrc.2004.06.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.06.076</ArticleId><ArticleId IdType="pmc">PMC7111066</ArticleId><ArticleId IdType="pubmed">15249217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap Y, Zhang X, Andonov A, He R. Structural analysis of inhibition mechanisms of aurintricarboxylic acid on SARS-CoV polymerase and other proteins. Comput Biol Chem. 2005;10(3):212&#x2013;219. doi: 10.1016/j.compbiolchem.2005.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiolchem.2005.04.006</ArticleId><ArticleId IdType="pmc">PMC7106521</ArticleId><ArticleId IdType="pubmed">15979041</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Chen TC, Fang MY, Yen KJ, Shih SR, Hsu JT, Tseng CP. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J Antimicrob Chemother. 2010;10(4):676&#x2013;683. doi: 10.1093/jac/dkp502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkp502</ArticleId><ArticleId IdType="pmc">PMC7110181</ArticleId><ArticleId IdType="pubmed">20089540</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Stollar V, Li ML. Host factors in enterovirus 71 replication. J Virol. 2011;10(19):9658&#x2013;9666. doi: 10.1128/JVI.05063-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05063-11</ArticleId><ArticleId IdType="pmc">PMC3196451</ArticleId><ArticleId IdType="pubmed">21715481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Li ML, Shih SR. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucleic Acids Res. 2009;10(1):47&#x2013;59. doi: 10.1093/nar/gkn901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn901</ArticleId><ArticleId IdType="pmc">PMC2615614</ArticleId><ArticleId IdType="pubmed">19010963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai F-J, Lin C-W, Lai C-C, Lan Y-C, Lai C-H, Hung C-H, Hsueh K-C, Lin T-H, Chang HC, Wan L. et al.Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. Food Chem. 2011;10(2):312&#x2013;322. doi: 10.1016/j.foodchem.2011.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2011.03.022</ArticleId><ArticleId IdType="pubmed">25212137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CY, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND. et al.Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-am ine. Inhibitors of rhinovirus multiplication. J Med Chem. 1980;10(4):368&#x2013;372. doi: 10.1021/jm00178a004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00178a004</ArticleId><ArticleId IdType="pubmed">6247489</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995;10(7):4189&#x2013;4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope DA, Diamond SE, Kirkegaard K. Genetic dissection of interaction between poliovirus 3D polymerase and viral protein 3AB. J Virol. 1997;10(12):9490&#x2013;9498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230255</ArticleId><ArticleId IdType="pubmed">9371611</ArticleId></ArticleIdList></Reference><Reference><Citation>Giachetti C, Hwang SS, Semler BL. Cis-acting lesions targeted to the hydrophobic domain of a poliovirus membrane protein involved in RNA replication. J Virol. 1992;10(10):6045&#x2013;6057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC241482</ArticleId><ArticleId IdType="pubmed">1326655</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Takebe Y, Wakita T, Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J Gen Virol. 2010;10(Pt 11):2734&#x2013;2744.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A. 2003;10(4):2014&#x2013;2018. doi: 10.1073/pnas.252783999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.252783999</ArticleId><ArticleId IdType="pmc">PMC149950</ArticleId><ArticleId IdType="pubmed">12566571</ArticleId></ArticleIdList></Reference><Reference><Citation>Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002;10(7):681&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042777</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature. 2002;10(6896):435&#x2013;438. doi: 10.1038/nature00896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature00896</ArticleId><ArticleId IdType="pmc">PMC9524216</ArticleId><ArticleId IdType="pubmed">12087358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature. 2002;10(6896):430&#x2013;434. doi: 10.1038/nature00873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature00873</ArticleId><ArticleId IdType="pubmed">12087357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim AC, Luhur A, Tan TM, Chow VT, Poh CL. RNA interference against enterovirus 71 infection. Virology. 2005;10(1):72&#x2013;79. doi: 10.1016/j.virol.2005.06.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.06.047</ArticleId><ArticleId IdType="pubmed">16083932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu WW, Hsu YY, Yang JY, Kung SH. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. Biochem Biophys Res Commun. 2004;10(2):494&#x2013;499. doi: 10.1016/j.bbrc.2004.10.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.10.062</ArticleId><ArticleId IdType="pubmed">15530419</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Tan TM, Tak Kwong Chow V, Poh CL. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol Ther. 2007;10(11):1931&#x2013;1938. doi: 10.1038/sj.mt.6300287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mt.6300287</ArticleId><ArticleId IdType="pubmed">17712333</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, Wang SM, Su IJ, Wang JR, Yeh TM, Chen SH. et al.Type I interferons protect mice against enterovirus 71 infection. J Gen Virol. 2005;10(Pt 12):3263&#x2013;3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, He Y, Chen Y, Kung HF, He ML. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antivir Ther. 2011;10(1):51&#x2013;58. doi: 10.3851/IMP1720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1720</ArticleId><ArticleId IdType="pubmed">21311108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis. 2011;10(12):1784&#x2013;1790. doi: 10.1093/infdis/jir174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir174</ArticleId><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Yi L, Zhao J, Yu J, Chen Y, Lin MC, Kung HF, He ML. Enterovirus 71 Disrupts Interferon Signaling by reducing the Interferon Receptor I. J Virol. 2012;10(7):3767&#x2013;3776. doi: 10.1128/JVI.06687-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06687-11</ArticleId><ArticleId IdType="pmc">PMC3302529</ArticleId><ArticleId IdType="pubmed">22258259</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut HJ, Leyssen P, Puerstinger G, Muigg A, Neyts J, De Palma AM. Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res. 2011;10(3):213&#x2013;217. doi: 10.1016/j.antiviral.2011.03.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.03.187</ArticleId><ArticleId IdType="pubmed">21466823</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S. et al.Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;10(3&#x2013;4):329&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY. A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol. 2004;10(Pt 1):69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, Su IJ, Wang JR, Yeh TM, Chen SH. et al.A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;10(15):7916&#x2013;7924. doi: 10.1128/JVI.78.15.7916-7924.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Shimizu H, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Miyamura T, Sata T, Iwasaki T. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol. 2002;10(2):207&#x2013;216. doi: 10.1002/jmv.2209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.2209</ArticleId><ArticleId IdType="pubmed">11992581</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Hasegawa H, Sata T, Miyamura T. et al.Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol. 2004;10(Pt 10):2981&#x2013;2989.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448361</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF. et al.Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine. 2008;10(23):2882&#x2013;2889. doi: 10.1016/j.vaccine.2008.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.03.041</ArticleId><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;10(15):2944&#x2013;2951. doi: 10.1016/j.vaccine.2005.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;10(5&#x2013;6):895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CW, Lee YP, Wang YF, Yu CK. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine. 2011;10(15):2772&#x2013;2776. doi: 10.1016/j.vaccine.2011.01.094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.094</ArticleId><ArticleId IdType="pubmed">21315698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;10(1):661&#x2013;665. doi: 10.1128/JVI.00999-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00999-09</ArticleId><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;10(22):3295&#x2013;3303. doi: 10.1016/j.vaccine.2012.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>